Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent advances: antiinfectives

L L Briceland1, J D Cleary, C V Fletcher

  • 1Albany College of Pharmacy, NY, USA.

The Annals of Pharmacotherapy
|October 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pretomanid dosing and pharmacokinetics in patients with TB in a high-resource setting.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same author

Impact of Pharmacogenetics on Pharmacokinetics of First-Line Antituberculosis Drugs in the HIRIF Trial.

The Journal of infectious diseases·2025
Same author

Surgical approach to model facial nerve paralysis in an ovine model for in vivo testing of a novel intervention.

Journal of plastic, reconstructive & aesthetic surgery : JPRAS·2025
Same author

Isoniazid urine spectrophotometry for prediction of serum pharmacokinetics in adults with TB.

IJTLD open·2024
Same author

Therapeutic drug monitoring for isoniazid and rifampicin exposure.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2024
Same author

Effect of HIV infection on plasma exposure to first-line TB drugs and target attainment in children.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2023
Same journal

Association Between Prior PARP Inhibitor Maintenance Therapy and Myelosuppression During Subsequent Chemotherapy in Ovarian Cancer.

The Annals of pharmacotherapy·2026
Same journal

Prolonged Response to Nivolumab in Metastatic Vulvar Carcinoma: Should Immunotherapy be Continued and for How Long? A Debatable Issue!

The Annals of pharmacotherapy·2026
Same journal

Stability of Ceftazidime-Avibactam: Changes in Regulatory Information and Implications for Preparation.

The Annals of pharmacotherapy·2026
Same journal

Impact of Early Dose Adjustment of Piperacillin/Tazobactam on Mortality in Critically Ill Patients With Acute Kidney Injury: A Retrospective Multicenter Cohort Study.

The Annals of pharmacotherapy·2026
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
See all related articles

Significant advancements in infectious diseases pharmacotherapy are reviewed, covering new treatments for peptic ulcer disease, microbial resistance, immunomodulators, and AIDS. This update highlights key developments since 1992.

Area of Science:

  • Infectious Diseases
  • Pharmacotherapy
  • Microbiology

Background:

  • Pharmacotherapy for infectious diseases is a rapidly evolving field.
  • Keeping abreast of new treatments and resistance patterns is crucial for effective patient care.

Purpose of the Study:

  • To provide an update on significant changes in infectious diseases pharmacotherapy.
  • To review recent developments in key therapeutic areas.

Main Methods:

  • Literature search of Index Medicus and Iowa Drug Information Service (1993-1994).
  • Inclusion of abstracts from scientific meetings.
  • Screening and evaluation of relevant studies.

Main Results:

  • Evaluation of new data related to peptic ulcer disease.

Related Experiment Videos

  • Analysis of emerging microbial resistance patterns (e.g., Enterococcus spp., Streptococcus pneumoniae, Mycobacterium tuberculosis, Candida albicans).
  • Review of advancements in immunomodulators and treatment for Acquired Immunodeficiency Syndrome (AIDS).

    • Conclusions:

    • The review identifies several exciting and significant changes in infectious diseases pharmacotherapy.
    • These updates are critical for clinicians managing infectious diseases.